Production (Stage)
Beam Therapeutics Inc.
BEAM
$16.83
-$0.41-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 63.58M | 63.52M | 349.64M | 352.57M | 360.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.58M | 63.52M | 349.64M | 352.57M | 360.91M |
| Cost of Revenue | 298.48M | 300.39M | 339.02M | 344.81M | 355.38M |
| Gross Profit | -234.90M | -236.87M | 10.62M | 7.75M | 5.53M |
| SG&A Expenses | 112.74M | 111.53M | 126.12M | 125.02M | 120.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 494.30M | 479.09M | 532.32M | 537.00M | 542.60M |
| Operating Income | -430.72M | -415.57M | -182.67M | -184.44M | -181.69M |
| Income Before Tax | -387.30M | -376.70M | -142.19M | -141.61M | -133.37M |
| Income Tax Expenses | 39.00K | 39.00K | 1.41M | 1.41M | 1.37M |
| Earnings from Continuing Operations | -387.34 | -376.74 | -143.59 | -143.01 | -134.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -387.34M | -376.74M | -143.59M | -143.01M | -134.74M |
| EBIT | -430.72M | -415.57M | -182.67M | -184.44M | -181.69M |
| EBITDA | -408.70M | -393.64M | -160.83M | -162.88M | -160.89M |
| EPS Basic | -4.61 | -4.58 | -1.72 | -1.76 | -1.74 |
| Normalized Basic EPS | -2.80 | -2.77 | -0.99 | -0.99 | -1.09 |
| EPS Diluted | -4.62 | -4.58 | -1.76 | -1.81 | -1.78 |
| Normalized Diluted EPS | -2.80 | -2.77 | -1.01 | -1.01 | -1.11 |
| Average Basic Shares Outstanding | 335.52M | 329.25M | 327.28M | 323.89M | 317.92M |
| Average Diluted Shares Outstanding | 335.52M | 329.25M | 329.12M | 325.74M | 319.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |